Joslyn S. Kirby

Penn State Milton S. Hershey Medical Center — United States

Medicine · Health Sciences

34h-index4.7kcitations227works7.82yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hidradenitis Suppurativa and Treatments(138), Colorectal and Anal Carcinomas(91), Microscopic Colitis(40), Chemotherapy-related skin toxicity(20), Anorectal Disease Treatments and Outcomes(14)

Publications226 total

Experiences of Drainage and Associated Impacts: A Qualitative Study Among Patients With Hidradenitis Suppurativa

JEADV Clinical Practice·2026Open Access

Establishment of standardized definitions and a core set of outcome characteristics following hidradenitis suppurativa surgery developed by an expert Delphi consensus

1 cited

Journal of the American Academy of Dermatology·2025· 1 citedOpen Access

The HIdradenitis suppurativa DrainagE (HIDE) scale: development and content validation of a patient reported outcome measure

2 cited

British Journal of Dermatology·2025· 2 cited

0203 HS progress: Baseline characteristics and disease impact

Journal of Investigative Dermatology·2025Open Access

Guidance on COVID-19 Vaccination in Hidradenitis Suppurativa Patients: A Modified Delphi Consensus of Experts

UNC Libraries·2025Open Access

Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL©) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa

1 cited

British Journal of Dermatology·2025· 1 citedOpen Access

The development and content validation of an instrument to measure drainage in HS:The HISTORIC Drainage Scale

University of Southern Denmark Research Portal (University of Southern Denmark)·2025

Development and External Validation of the Hidradenitis Suppurativa Cutaneous Abscess Prediction Score-2: A Clinical Decision Support Tool for Diagnosis of Hidradenitis Suppurativa over Cutaneous Abscess

Dermatology·2025

North American clinical practice guidelines for the medical management of hidradenitis suppurativa in special patient populations

6 cited

Journal of the American Academy of Dermatology·2024· 6 cited

Pilot study of topical ruxolitinib demonstrates efficacy and blunting of heterogeneous inflammatory processes in mild hidradenitis suppurativa

9 cited

British Journal of Dermatology·2024· 9 cited

Editor's Note

Journal of Critical Race Inquiry·2024Open Access

Psychometric properties of the revised internalized skin bias questionnaire

1 cited

Journal of the European Academy of Dermatology and Venereology·2024· 1 citedOpen Access

Trends of Metformin Use in Patients with Hidradenitis Suppurativa, 2016-2021

SKIN The Journal of Cutaneous Medicine·2024Open Access

52682 Revealing patient perspectives on hidradenitis suppurativa according to racial background: Results from a global study

1 cited

Journal of the American Academy of Dermatology·2024· 1 cited

52655 Impact of hidradenitis suppurativa on patients' work and productivity: Results from the HS Uncovered global patient survey

Journal of the American Academy of Dermatology·2024

54563 Trends in surgical management of hidradenitis suppurativa in the Medicare population

Journal of the American Academy of Dermatology·2024

Advances in Hidradenitis Suppurativa Pathogenesis and Therapies from the Symposium on HS Advances 2023

5 cited

Journal of Investigative Dermatology·2024· 5 citedOpen Access

278 Topical ruxolitinib is efficacious for early stage hidradenitis suppurativa by blunting heterogeneous inflammatory processes

Journal of Investigative Dermatology·2024Open Access

Early postoperative water exposure does not increase complications in cutaneous surgeries: A randomized, investigator-blinded, controlled trial

Journal of the American Academy of Dermatology·2024

Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials

128 cited

The Lancet·2024· 128 citedOpen Access

page 1 of 12Next →

Frequent Co-authors

Amit Garg(12), John R Ingram(12), Gregor B. E. Jemec(12), Afsáneh Alavi(11), Michelle A. Lowes(11), Melissa Butt(10), Iltefat Hamzavi(9), Haley B. Naik(9), Christopher J. Sayed(8), Falk G. Bechara(8), Jerry Tan(8), Alexa B. Kimball(7), Solveig Esmann(7), Linnea Thorlacius(7), Bente Villumsen(7), Errol P. Prens(7), Christos C. Zouboulis(7), Robert G. Micheletti(6), Alice B. Gottlieb(5), Jacek C. Szepietowski(5)